Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in @entity583 : influence of heparin on early patency rate (LIMITS study). Liquemin in XXXX During Thrombolysis With Saruplase.

@entity1 @entity2002 @entity548 @entity26782 @entity1188 @entity56 @entity583
OBJECTIVES: The Liquemin in @entity583 During Thrombolysis With Saruplase (LIMITS) study was instituted to evaluate and characterize the effect of a prethrombolytic heparin bolus (5,000 IU) on the efficacy and safety of saruplase in @entity1 with @entity583 . BACKGROUND: Heparin has been used after thrombolytic therapy for @entity583 to prevent reocclusion of the @entity1188 . METHODS: The study was designed as a randomized, parallel-group, double-blind, multicenter trial. @entity1 were treated within 6 h of onset of symptoms with either a bolus of 5,000 IU of heparin (Liquemin) (n = 56, HSH group) or placebo (n = 62, @entity26782 group) before thrombolytic treatment with saruplase given as a 20-mg bolus followed by an infusion of 60 mg over 60 min. Thirty minutes after completion of thrombolysis, an intravenous heparin infusion was administered for 5 days. Before coronary angiography was performed at 6 to 12 h after start of lysis, an additional bolus of 5,000 IU heparin was given to all @entity1 . End points studied were patency of the @entity1188 , changes in the hemostatic system and @entity548 complications. RESULTS: In the HSH group (heparin-saruplase-heparin), 78.6% of @entity1 had an open @entity1188 -related vessel (Thrombolysis in @entity583 [TIMI] flow grade 2 or 3) compared with 56.5% in the @entity26782 group (placebo-saruplase-heparin) (intention-to-treat analysis, p = 0.01). No significant difference was observed between the two groups with regard to changes in @entity2002 and fibrin/ @entity2002 degradation products. A total of eight @entity548 complications (14.3%) were observed in the HSH group and five (8.1%) in the @entity26782 group; no cerebrovascular event occurred, and no @entity56 was reported. A total of 12 @entity1 died during the hospital stay, 3 in the HSH group (5.4%) and 9 in the @entity26782 group (14.5%). CONCLUSIONS: In @entity583 , the administration of a heparin bolus before thrombolytic therapy with saruplase is associated with a significantly higher patency at angiography 6 to 12 h after the start of thrombolysis without any appreciable increase in risk of @entity548 .
